Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31524255 | 1.00 | SLC7A5 (0.56) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL12803446 | 1.00 | SLC7A5 (0.56) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL188320 | 0.89 | SLC7A5 (0.57) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL2129884 | 0.89 | SLC7A5 (0.57) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL188321 | 0.89 | SLC7A5 (0.57) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL1483094 | 0.87 | SLC7A5 (0.66) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL1483095 | 0.87 | SLC7A5 (0.66) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL5560750 | 0.83 | SLC7A5 (0.56) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| Glycine SCHEMBL28732579 | 0.83 | SLC7A5 (0.50) | SLC7A5USP2HSD17B10ALOX15ADORA3 | |
| SCHEMBL845967 | 0.81 | SLC7A5 (0.49) | SLC7A5USP2HSD17B10ALOX15ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568976-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | Aviko Radiopharmaceuticals, LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024035871-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3427737-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NeuroVive Pharmaceutical AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251581-A1 | Novel Compound and Methods for its Production | Abliva Ab (SE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131371-A1 | MACROCYCLIC COMPOUND AND METHODS FOR ITS PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | SLC7A5 56/4885USP2 2664/4885HSD17B10 3071/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | SLC7A5 1425/4885USP2 4542/4885HSD17B10 1042/4885 |
| US-20120251581-A1 | Novel Compound and Methods for its Production | EIF2AK2, HAVCR2, CYP51A1 | SLC7A5 2824/4885USP2 3987/4885HSD17B10 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.